Table Info

Table 2.

FAPI and FET PET imaging interpretation & follow up data

Patient	MRI findings			FET* PET**	FAPI PET	Diagnosis	Follow-up
Patient	T1 post-contrast	Perfusion	BT-RADS	FET* PET**	FAPI PET	Diagnosis	Follow-up
1	Nodular enhancement	Hyper	3C**	2.9	Positive	Recurrence	Re-surgery, HPR—Grade IV GBM
2	Nodular enhancement	Hyper	3C	4.07	Positive	Recurrence	Salvage TMZ
3	Irregular enhancement “Swiss cheese” pattern	Iso	3B*	2.5	Negative	Post-treatment changes	Follow-up MRI—no change
4	Nodular enhancement	Hyper	3B	3.6	Positive	Recurrence	Salvage TMZ
5	Nodular enhancement	Iso	3B	5.9	Positive	Recurrence	On Bevacizumab
6	Nodular enhancement “Swiss cheese” pattern	Hyper	3C	4.0	Positive	Recurrence	Salvage TMZ

BT-RADS 3B*: indeterminate mix of treatment effect and tumor progression [13]; BT-RADS 3C**: tumor progression favored [13]; FET PET***: tumor-to-white mater cut-off of 2.62 to differentiate between recurrence and post treatment changes [8]; HPR: histopathology report; GBM: glioblastoma; TMZ: temozolamide; MRI: magnetic resonance imaging; FAP: fibroblast-activated protein; FET: fluoro-ethyl tyrosine

Declarations

Author contributions

IDD: Conceptualization, Data curation, Writing—original draft, Formal analysis. ADP: Writing—review & editing. VR: Project administration. SP: Supervision, Software. NP: Methodology. A Sahu, A Choudhary, KB: Methodology. TG, A Chatterjee, AD, AM, PS, VS, ES, A Sahay, A Shah: Resources. SG, SC, SS and AA: Validation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the Institutional Ethics Committee (Tata Memorial Hospital, Mumbai) with Project Approval No 4238.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

Not applicable.

Copyright

References

Nakajima T, Kumabe T, Kanamori M, Saito R, Tashiro M, Watanabe M, et al. Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurol Med Chir (Tokyo). 2009;49:394–401. [DOI] [PubMed]

Bashir A, Mathilde Jacobsen S, Mølby Henriksen O, Broholm H, Urup T, Grunnet K, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine positron emission tomography (¹⁸F-FET PET). Neuro Oncol. 2019;21:1595–606. [DOI]

Unterrainer M, Schweisthal F, Suchorska B, Wenter V, Schmid-Tannwald C, Fendler WP, et al. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense? J Nucl Med. 2016;57:1177–82. [DOI] [PubMed]

Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53:207–14. [DOI] [PubMed]

Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S, Aghi MK. The Role of Cancer-Associated Fibroblasts in Tumor Progression. Cancers (Basel). 2021;13:1399. [DOI] [PubMed] [PMC]

Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, et al. New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals (Basel). 2021;14:1023. [DOI] [PubMed] [PMC]

Hathi DK, Jones EF. ⁶⁸Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiol Imaging Cancer. 2019;1:e194003. [DOI] [PubMed] [PMC]

Puranik AD, Rangarajan V, Dev ID, Jain Y, Purandare NC, Sahu A, et al. Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. J Neuroimaging. 2021;31:1211–8. [DOI] [PubMed]

Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:2569–80. [DOI] [PubMed]

10.

Busek P, Balaziova E, Matrasova I, Hilser M, Tomas R, Syrucek M, et al. Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma. Tumour Biol. 2016;37:13961–71. [DOI] [PubMed]

11.

Tensaouti F, Khalifa J, Lusque A, Plas B, Lotterie JA, Berry I, et al. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. Neuroradiology. 2017;59:1013–20. [DOI] [PubMed]

12.

Röhrich M, Floca R, Loi L, Adeberg S, Windisch P, Giesel FL, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. Eur J Radiol. 2020;127:109021. [DOI] [PubMed]

13.

Weinberg BD, Gore A, Shu HG, Olson JJ, Duszak R, Voloschin AD, et al. Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System. J Am Coll Radiol. 2018;15:767–71. [DOI] [PubMed]

14.

Vettermann FJ, Diekmann C, Weidner L, Unterrainer M, Suchorska B, Ruf V, et al. L-type amino acid transporter (LAT) 1 expression in ¹⁸F-FET-negative gliomas. EJNMMI Res. 2021;11:124. [DOI] [PubMed] [PMC]

15.

Windisch P, Röhrich M, Regnery S, Tonndorf-Martini E, Held T, Lang K, et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol. 2020;150:159–63. [DOI] [PubMed]